Resverlogix 2019 Poster titled:  “Apabetalone (RVX208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism:

https://www.resverlogix.com/upload/media_element/178/16e78195f8e4/2019-09-03-esc-vi-poster-final.pdf 

Both HGMB1 and TGFB1 pathways are noted to be downregulated by ABL if I am reading this 2019 ESC poster correctly.  These seem to be two key pathways the paper suggests are pro-viral. 

I remain hopeful that RVX is going to stall  COVID-19 replication.  Keep in mind I’m not a researcher, but I am excited for the future of RVX; wish it was quicker, as we all do ;)